No nothing to do with Lizards:-) but the Jabs…..Well done MS-Britain you want the Jab…but let’s finish the job/jab
- •94.4% of people with multiple sclerosis (MS) would accept a COVID-19 vaccine
- •People of increasing age and influenza vaccinations were more likely to accept
- •Safety concerns and lack of information were top reasons for not getting a vaccine
- •51.7% of people with MS initially surveyed received a COVID-19 vaccine by May 2021
- •Deciding to receive a vaccine changes with evolving perceived risk versus benefit
Huang et al. Willingness to receive a COVID-19 vaccine in people with multiple sclerosis – UK MS Register Survey MSARS, 2021DOI:https://doi.org/10.1016/j.msard.2021.103175
Background & Methods: We conducted an online COVID-19 survey as the vaccines became available, utilising the UK MS Register, to understand people with multiple sclerosis (pwMS) views on COVID-19 vaccination and the subsequent vaccine uptake rates.
Results & Conclusion: 94.4% of 3191 pwMS surveyed indicated they would get a COVID-19 vaccine, while 5.6% would not. PwMS who have previously had an influenza vaccine, increasing age and the perception of having sufficient information about the vaccine were associated with increased likelihood of getting a vaccine. 51.7% of 3191 pwMS completed a follow-up survey indicating they received at least 1 dose of a COVID-19 vaccine. The proportion having had the vaccination based on their prior opinions was 53.2% in ‘Yes’ group and 27.0% in ‘No’ group, the latter reflecting a change based on their initial views. More information on COVID-19 vaccine safety in pwMS would be helpful for people to make informed decisions.
So we have to ask the question of the 6% what are your reasons against and then we can work through these….So look at c below Safety concerns is top of the list remember the risk of blood clots is less than the risk of the bloodclot from flying,……taking certain medicines and the risks of not being vaccinated are probably higher. Uncomfortable doing it in a Health care environment…..they were being done in vaccination centres in football stadia, if you were a gooner you could have got a look round Arsenal…Oops I can see why you wouldnt want to do that:-)
Remember to sign up to the MS regisister
Uhr L, Mateen FJ. COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey. Mult Scler. 2021 Jul 27:13524585211030647. doi: 10.1177/13524585211030647. Epub ahead of print. PMID: 34313513.
However our friends in the US are not quite as up for it and 76.6% were COVID-19 vaccine willing
Background: Vaccine willingness among people living with multiple sclerosis (PwMS) requires assessment following the approval of the first COVID-19 vaccines, since there remains uncertainty on multiple aspects of COVID-19 vaccination in immunosuppressed patients.
Objective: To understand COVID-19 and influenza vaccine willingness and its associations among PwMS, following the approval of the first two mRNA COVID-19 vaccines.
Methods: A survey was distributed to PwMS via an online platform from December 2020 to February 2021. Logistic regression models were constructed to determine the relationship between (1) COVID-19 and (2) influenza vaccination willingness with demographic and clinical characteristics.
Results: Of 701 responding PwMS, 76.6% were COVID-19 vaccine willing. COVID-19 vaccine willingness was significantly associated with influenza vaccine willingness (p < 0.001). In multivariable models, older age increased the odds of COVID-19 and influenza vaccine willingness (odds ratios (ORs) > 1) and other race decreased the odds of COVID-19 and influenza vaccine willingness (ORs < 1); higher functional disability decreased the odds of COVID-19 vaccine willingness (OR = 0.88, 95% confidence interval = 0.80-0.96). Prevalent vaccine-related concerns include safety (n = 244) and efficacy (n = 122).
Conclusion: Our findings identify demographic and clinical factors as well as concerns influencing vaccine hesitancy in PwMS. These results may inform effective public health interventions to improve vaccine acceptability in this at-risk group.